Home › Posts tagged Follicular Lymphoma (FL)

Tag: Follicular Lymphoma (FL)

By Posted on Posted in Adverse Drug Reaction [ADR], Market Withdrawal, Regulatory Announcement, Thasso Post, Theragenomic Medicine No Comments Tagged with , , , , , , , , , , , ,

May 08, 2022 – Umbralisib (Ukoniq) is a medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). Umbralisib (Ukoniq) inhibits multiple kinases. In biochemical and cell-based assays, Umbralisib inhibited PI3Kδ and casein kinase CK1ε. PI3Kδ is expressed in …

Umbralisib (Ukoniq): Drug recall because increased risk of patient death Read more »

By Posted on Posted in Adverse Drug Reaction [ADR], New Safety Information, Thasso Post, Theragenomic Medicine Tagged with , , , , , , , ,

 March 20, 2016 – The European Medicines Agency (EMA) has, at the request of the European Commission, has started a review of the cancer medicine Idelalisib (Zydelig), which is authorised in the European Union to treat two types of rare blood cancers called …

Under scrutiny: The EMA reviews cancer medicine Idelalisib (Zydelig) after the occurrence of serious adverse effects, some of them fatal, in three clinical trials Read more »

By Posted on Posted in New Drug Approval, New Indication Approval, Regulatory Approval, Thasso Post, Theragenomic Medicine Tagged with , , , , ,

February 26, 2016 – Two new treatments for oncologic indications have been approved by the American Food and Drug Administration (FDA). Thus, the FDA approved Obinutuzumab (Gazyva) for use in combination with bendamustine followed by Obinutuzumab (Gazyva) monotherapy for the treatment of patients with follicular …

News for Obinutuzumab (Gazyva) and Everolimus (Afinitor) Read more »